195 related articles for article (PubMed ID: 10552969)
1. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.
Yaccoby S; Epstein J
Blood; 1999 Nov; 94(10):3576-82. PubMed ID: 10552969
[TBL] [Abstract][Full Text] [Related]
2. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
Yaccoby S; Barlogie B; Epstein J
Blood; 1998 Oct; 92(8):2908-13. PubMed ID: 9763577
[TBL] [Abstract][Full Text] [Related]
3. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
4. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma-initiating cells.
Hosen N
Int J Hematol; 2013 Mar; 97(3):306-12. PubMed ID: 23420183
[TBL] [Abstract][Full Text] [Related]
6. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Yaccoby S; Pearse RN; Johnson CL; Barlogie B; Choi Y; Epstein J
Br J Haematol; 2002 Feb; 116(2):278-90. PubMed ID: 11841428
[TBL] [Abstract][Full Text] [Related]
7. The SCID-hu myeloma model.
Epstein J; Yaccoby S
Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
[TBL] [Abstract][Full Text] [Related]
8. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma efficacy of thalidomide in the SCID-hu model.
Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J
Blood; 2002 Dec; 100(12):4162-8. PubMed ID: 12393672
[TBL] [Abstract][Full Text] [Related]
10. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
[TBL] [Abstract][Full Text] [Related]
11. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
12. The development of a model for the homing of multiple myeloma cells to human bone marrow.
Urashima M; Chen BP; Chen S; Pinkus GS; Bronson RT; Dedera DA; Hoshi Y; Teoh G; Ogata A; Treon SP; Chauhan D; Anderson KC
Blood; 1997 Jul; 90(2):754-65. PubMed ID: 9226176
[TBL] [Abstract][Full Text] [Related]
13. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
14. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
Huang SY; Tien HF; Su FH; Hsu SM
Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
[TBL] [Abstract][Full Text] [Related]
15. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
[TBL] [Abstract][Full Text] [Related]
16. A clinically relevant SCID-hu in vivo model of human multiple myeloma.
Tassone P; Neri P; Carrasco DR; Burger R; Goldmacher VS; Fram R; Munshi V; Shammas MA; Catley L; Jacob GS; Venuta S; Anderson KC; Munshi NC
Blood; 2005 Jul; 106(2):713-6. PubMed ID: 15817674
[TBL] [Abstract][Full Text] [Related]
17. Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice.
Chen BP; Galy A; Kyoizumi S; Namikawa R; Scarborough J; Webb S; Ford B; Cen DZ; Chen SC
Blood; 1994 Oct; 84(8):2497-505. PubMed ID: 7522631
[TBL] [Abstract][Full Text] [Related]
18. Long-term engraftment of fresh human myeloma cells in SCID mice.
Feo-Zuppardi FJ; Taylor CW; Iwato K; Lopez MH; Grogan TM; Odeleye A; Hersh EM; Salmon SE
Blood; 1992 Dec; 80(11):2843-50. PubMed ID: 1450409
[TBL] [Abstract][Full Text] [Related]
19. CD19 expression and growth inhibition of tumours in human multiple myeloma.
Ishikawa H; Tsuyama N; Mahmoud MS; Fujii R; Abroun S; Liu S; Li FJ; Kawano MM
Leuk Lymphoma; 2002 Mar; 43(3):613-6. PubMed ID: 12002767
[TBL] [Abstract][Full Text] [Related]
20. Mature human hematopoietic cells in donor bone marrow complicate interpretation of stem/progenitor cell assays in xenogeneic hematopoietic chimeras.
RamÃrez M; Rottman GA; Shultz LD; Civin CI
Exp Hematol; 1998 Apr; 26(4):332-44. PubMed ID: 9546317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
